• News
  • SAN DIEGO
  • BioTech

Cytori appoints Kesten as executive VP, chief medical officer

San Diego-based Cytori Therapeutics (Nasdaq: CYTX) appointed Steven Kesten, M.D., as executive vice president and chief medical officer. In this role, Kesten will lead global clinical development operations and Cytori’s medical affairs activities.

Kesten served as vice president and chief medical officer at Uptake Medical, where he oversaw the completion of the Vapor trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor.

He served for more than 10 years at Boehringer Ingelheim, most recently as the vice president in medicine for marketed products for respiratory disease. During his tenure, Kesten was responsible for the development and execution of large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva, a $3 billion worldwide product for chronic obstructive pulmonary disease. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.

In addition, Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago.

He received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.

RELATED ARTICLES:

Cytori gets OK in Japan for stem cell study

CareFusion medical chief focusing on product innovation

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Cytori Therapeutics

Company Website

3020 Callan Road
San Diego, CA 92121

Subscribe Today!